Neurotrophin-3 modulates breast cancer cells and the microenvironment to promote the growth of breast cancer brain metastasis

Oncogene

Volumn 32, Issue 35, 2013, Pages 4064-4077

  Louie, E ^a   Chen, X F ^a   Coomes, A ^a   Ji, K ^a   Tsirka, S ^a   Chen, E I ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

brain metastasis; breast cancer; HER2 positive; HER2 signaling; neurotrophin 3; protein signature

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; NEUROTROPHIN 3; SHORT HAIRPIN RNA; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN METASTASIS; BREAST CANCER; BREAST TUMOR; CANCER CELL CULTURE; CANCER GROWTH; CELL INTERACTION; CELL JUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; LATENT PERIOD; MICROGLIA; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TROPISM; TUMOR MICROENVIRONMENT;

ANIMALS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; IMMUNE EVASION; MICE; MICE, SCID; NEUROTROPHIN 3; RECEPTOR, ERBB-2; RECEPTOR, TRKA; TUMOR MICROENVIRONMENT;

EID: 84883487600     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.417     Document Type: Article

References (54)

1. Welch DR, Steeg PS, Rinker-Schaeffer CW. Molecular biology of breast cancer metastasis. Genetic regulation of human breast carcinoma metastasis. Breast Cancer Res 2000; 2: 408-416.
2. Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS. Breast cancer metastasis to the central nervous system. Am J Pathol 2005; 167: 913-920.
3. Price JE. Metastasis from human breast cancer cell lines. Breast Cancer Res Treat 1996; 39: 93-102.
4. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD et al. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436: 518-524.
5. Lu X, Kang Y. Organotropism of breast cancer metastasis. J Mammary Gland Biol Neoplasia 2007; 12: 153-162.
6. Ohno S, Ishida M, Kataoka A, Murakami S. Brain metastasis of breast cancer. Breast Cancer 2004; 11: 27-29.
7. Kirsch DG, Loeffler JS. Brain metastases in patients with breast cancer: new horizons. Clin Breast Cancer 2005; 6: 115-124.
8. Chang EL, Lo S. Diagnosis and management of central nervous system metastases from breast cancer. Oncologist 2003; 8: 398-410.
9. Puduvalli VK. Brain metastases: biology and the role of the brain microenvironment. Curr Oncol Rep 2001; 3: 467-475.
10. Nathoo N, Chahlavi A, Barnett GH, Toms SA. Pathobiology of brain metastases. J Clin Pathol 2005; 58: 237-242.
11. Tomasevic Z, Radosevic-Jelic L, Jovanovic D, Milovanovic Z, Tomasevic ZM, Jelic S et al. Brain metastases as late breast cancer relapse. Single institution experience and review of the literature. J BUON 2009; 14: 225-228.
12. Piccirilli M, Sassun TE, Brogna C, Giangaspero F, Salvati M. Late brain metastases from breast cancer: clinical remarks on 11 patients and review of the literature. Tumori 2007; 93: 150-154.
13. Chen EI, Hewel J, Krueger JS, Tiraby C, Weber MR, Kralli A et al. Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res 2007; 67: 1472-1486.
14. Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 2003; 72: 609-642.
15. Adriaenssens E, Vanhecke E, Saule P, Mougel A, Page A, Romon R et al. Nerve growth factor is a potential therapeutic target in breast cancer. Cancer Res 2008; 68: 346-351.
16. Descamps S, Pawlowski V, Revillion F, Hornez L, Hebbar M, Boilly B et al. Expression of nerve growth factor receptors and their prognostic value in human breast cancer. Cancer Res 2001; 61: 4337-4340.
17. Vanhecke E, Adriaenssens E, Verbeke S, Meignan S, Germain E, Berteaux N et al. Brain-derived neurotrophic factor and neurotrophin-4/5 are expressed in breast cancer and can be targeted to inhibit tumor cell survival. Clin Cancer Res 2011; 17: 1741-1752.
18. Hondermarck H. Nerve growth factor: the dark side of the icon. Am J Pathol 2008; 172: 865-867.
19. Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 2003; 5: R217-R222.
20. Chao YL, Shepard CR, Wells A. Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer 2010; 9: 179.
21. Chaffer CL, Dopheide B, McCulloch DR, Lee AB, Moseley JM, Thompson EW et al. Upregulated MT1-MMP/TIMP-2 axis in the TSU-Pr1-B1/B2 model of metastatic progression in transitional cell carcinoma of the bladder. Clin Exp Metastasis 2005; 22: 115-125.
22. Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 2006; 66: 11271-11278.
23. Yates CC, Shepard CR, Stolz DB, Wells A. Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. Br J Cancer 2007; 96: 1246-1252.
24. Oltean S, Sorg BS, Albrecht T, Bonano VI, Brazas RM, Dewhirst MW et al. Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. Proc Natl Acad Sci USA 2006; 103: 14116-14121.
25. Vincan E, Darcy PK, Smyth MJ, Thompson EW, Thomas RJ, Phillips WA et al. Frizzled-7 receptor ectodomain expression in a colon cancer cell line induces morphological change and attenuates tumor growth. Differentiation 2005; 73: 142-153.
26. He BP, Wang JJ, Zhang X, Wu Y, Wang M, Bay BH et al. Differential reactions of microglia to brain metastasis of lung cancer. Mol Med 2006; 12: 161-170.
27. Fitzgerald DP, Palmieri D, Hua E, Hargrave E, Herring JM, Qian Y et al. Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin Exp Metastasis 2008; 25: 799-810.
28. Tzeng SF, Huang HY, Lee TI, Jwo JK. Inhibition of lipopolysaccharide- induced microglial activation by preexposure to neurotrophin-3. J Neurosci Res 2005; 81: 666-676.
29. Elkabes S, DiCicco-Bloom EM, Black IB. Brain microglia/macrophages express neurotrophins that selectively regulate microglial proliferation and function. J Neurosci 1996; 16: 2508-2521.
30. Tagliabue E, Castiglioni F, Ghirelli C, Modugno M, Asnaghi L, Somenzi G et al. Nerve growth factor cooperates with p185(HER2) in activating growth of human breast carcinoma cells. J Biol Chem 2000; 275: 5388-5394.
31. Matsumura H, Ohnishi T, Kanemura Y, Maruno M, Yoshimine T. Quantitative analysis of glioma cell invasion by confocal laser scanning microscopy in a novel brain slice model. Biochem Biophys Res Commun 2000; 269: 513-520.
32. Jung S, Kim HW, Lee JH, Kang SS, Rhu HH, Jeong YI et al. Brain tumor invasion model system using organotypic brain-slice culture as an alternative to in vivo model. J Cancer Res Clin Oncol 2002; 128: 469-476.
33. Cho S, Wood A, Bowlby MR. Brain slices as models for neurodegenerative disease and screening platforms to identify novel therapeutics. Curr Neuropharmacol 2007; 5: 19-33.
34. Menon MB, Ronkina N, Schwermann J, Kotlyarov A, Gaestel M. Fluorescencebased quantitative scratch wound healing assay demonstrating the role of MAPKAPK-2/3 in fibroblast migration. Cell Motil Cytoskeleton 2009; 66: 1041-1047.
35. Yarrow JC, Perlman ZE, Westwood NJ, Mitchison TJ. A high-throughput cell migration assay using scratch wound healing, a comparison of image-based readout methods. BMC Biotechnol 2004; 4: 21.
36. Louie E, Nik S, Chen JS, Schmidt M, Song B, Pacson C et al. Identification of a stemlike cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation. Breast Cancer Res 2010; 12: R94.
37. Yonemori K, Tsuta K, Ono M, Shimizu C, Hirakawa A, Hasegawa T et al. Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer 2010; 116: 302-308.
38. Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 2007; 7: 161-167.
39. Ohsawa K, Imai Y, Sasaki Y, Kohsaka S. Microglia/macrophage-specific protein Iba1 binds to fimbrin and enhances its actin-bundling activity. J Neurochem 2004; 88: 844-856.
40. Klos KJ, O'Neill BP. Brain metastases. Neurologist 2004; 10: 31-46.
41. Kwon HC, Oh SY, Kim SH, Lee S, Kwon KA, Choi YJ et al. Clinical outcomes and breast cancer subtypes in patients with brain metastases. Onkologie 33: 146-152.
42. Trimboli AJ, Fukino K, de Bruin A, Wei G, Shen L, Tanner SM et al. Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res 2008; 68: 937-945.
43. Tse JC, Kalluri R. Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem 2007; 101: 816-829.
44. Montel V, Huang TY, Mose E, Pestonjamasp K, Tarin D. Expression profiling of primary tumors and matched lymphatic and lung metastases in a xenogeneic breast cancer model. Am J Pathol 2005; 166: 1565-1579.
45. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008; 13: 58-68.
46. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer 2006; 6: 449-458.
47. Kim JW, Wong CW, Goldsmith JD, Song C, Fu W, Allion MB et al. Rapid apoptosis in the pulmonary vasculature distinguishes non-metastatic from metastatic melanoma cells. Cancer Lett 2004; 213: 203-212.
48. MacDonald IC, Groom AC, Chambers AF. Cancer spread and micrometastasis development: quantitative approaches for in vivo models. Bioessays 2002; 24: 885-893.
49. Choi YH, Ahn JH, Kim SB, Jung KH, Gong GY, Kim MJ et al. Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis. Ann Oncol 2009; 20: 1337-1343.
50. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97: 2972-2977.
51. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008; 26: 1993-1999.
52. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112: 533-543.
53. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.
54. Palmieri D, Bronder JL, Herring JM, Yoneda T, Weil RJ, Stark AM et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 2007; 67: 4190-4198.